Ganciclovir ophthalmic gel 0.15%: Safety and efficacy of a new treatment for herpes simplex keratitis

Current Eye Research

Volumn 37, Issue 7, 2012, Pages 654-660

  Kaufman, Herbert E ^a   Haw, Weldon H ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Acyclovir; Adenoviral keratoconjunctivitis; Ganciclovir ophthalmic gel 0.15 ; Herpes simplex keratitis; Trifluridine

Indexed keywords

ACICLOVIR; GANCICLOVIR; TRIFLURIDINE;

ADENOVIRUS INFECTION; ANTIVIRAL ACTIVITY; ARTICLE; BLURRED VISION; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EYE IRRITATION; EYELID ERYTHEMA; GEL; HERPES SIMPLEX KERATITIS; HUMAN; KERATOCONJUNCTIVITIS; NONHUMAN; OINTMENT; PRIORITY JOURNAL; PUNCTATE KERATITIS; SYSTEMATIC REVIEW;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GANCICLOVIR; GELS; HUMANS; KERATITIS, HERPETIC; OPHTHALMIC SOLUTIONS; PRODUCT SURVEILLANCE, POSTMARKETING; TREATMENT OUTCOME;

EID: 84862160795     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2012.692846     Document Type: Article

References (47)

1. Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci 2005;46:241-247. (Pubitemid 40041203)
2. Khan BF, Pavan-Langston D. Clinical manifestations and treatment modalities in herpes simplex virus of the ocular anterior segment. Int Ophthalmol Clin 2004;44:103-133. (Pubitemid 38955665)
3. Labetoulle M, Auquier P, Conrad H et al. Incidence of herpes simplex virus keratitis in France. Ophthalmology 2005;112:888-895. (Pubitemid 40631511)
4. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 2001;20:1-13. (Pubitemid 32038147)
5. Liesegang TJ, Melton LJ 3rd, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989;107:1155-1159. (Pubitemid 19195642)
6. Kaufman HE. Ganciclovir: a promising topical antiviral gel for herpetic keratitis. Expert Rev Ophthalmol 2009;4:367-375.
7. Kaufman HE, Maloney ED, Nesburn AB. Comparison of specific antiviral agents in herpes simplex keratitis. Invest Ophthalmol 1962;1:686-692.
8. Kaufman H, Martola EL, Dohlman C. Use of 5-iodo-2′-deoxy-uridine (IDU) in treatment of herpes simplex keratitis. Arch Ophthalmol 1962;68:235-239.
9. Kaufman HE, Nesburn AB, Maloney ED. IDU therapy of herpes simplex. Arch Ophthalmol 1962;67:583-591.
10. Wilhelmus KR. Therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2007;1:CD002898.
11. Guess S, Stone DU, Chodosh J. Evidence-based treatment of herpes simplex virus keratitis: a systematic review. Ocul Surf 2007;5:240-250. (Pubitemid 351902645)
12. Wellings PC, Awdry PN, Bors FH, Jones BR, Brown DC, Kaufman HE. Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers. Am J Ophthalmol 1972;73:932-942.
13. Maudgal PC, Van Damme B, Missotten L. Corneal epithelial dysplasia after trifluridine use. Graefes Arch Clin Exp Ophthalmol 1983;220:6-12. (Pubitemid 13180380)
14. Udell IJ. Trifluridine-associated conjunctival cicatrization. Am J Ophthalmol 1985;99:363-364.
15. Bruno B, Gooley T, Hackman RC, Davis C, Corey L, Boeckh M. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant 2003;9:341-352. (Pubitemid 38351819)
16. Locarnini S, Guo K, Lucas R, Gust I. Inhibition of HBV DNA replication by ganciclovir in patients with AIDS. Lancet 1989;2:1225-1226. (Pubitemid 19275485)
17. Taylor DL, Jeffries DJ, Taylor-Robinson D, Parkin JM, Tyms AS. The susceptibility of adenovirus infection to the anticytomegalovirus drug, ganciclovir (DHPG). FEMS Microbiol Lett 1988;49: 337-341. (Pubitemid 18077621)
18. Sirion Therapeutics, Inc. New Drug Application 22-211:ST-605 (Ganciclovir Ophthalmic Gel, 0.15%). November 14, 2008.
19. Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol 2007;1:441-453.
20. Zirgan [package insert]. Rochester, NY: Bausch & Lomb, Inc; 2009.
21. Hoh HB, Hurley C, Claoue C et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol 1996;80:140-143. (Pubitemid 26058547)
22. Crumpacker CS. Ganciclovir. N Engl J Med 1996;335:721-729.
23. Castela N, Vermerie N, Chast F et al. Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy. J Ocul Pharmacol 1994;10:439-451. (Pubitemid 24186564)
24. Trousdale MD, Nesburn AB, Willey DE, Taaid H. Efficacy of BW759 (9-[[2-hydroxy-1(hydroxymethyl)ethoxy]methyl]guanine) against herpes simplex virus type 1 keratitis in rabbits. Curr Eye Res 1984;3:1007-1015. (Pubitemid 14030475)
25. Shiota H, Naito T, Mimura Y. Anti-herpes simplex virus (HSV) effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in rabbit cornea. Curr Eye Res 1987;6:241-245. (Pubitemid 17007680)
26. Varnell ED, Kaufman HE. Comparison of ganciclovir ophthalmic gel and trifluridine drops for the treatment of experimental herpetic keratitis. Presented at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology; April 27-May 1, 2008; Fort Lauderdale, FL.
27. Chibrel H, Elena PP, Khosravi E. Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed epithelium. Invest Ophthalmol Vis Sci 1993;34:1712-1734.
28. Lowe E, Jiang S, Proksch JW. Rapid ocular penetration of ganciclovir with topical administration of Zirgan® to rabbits. Poster presented at the 2011 Annual Meeting of the Association for Research in Vision and Ophthalmology; April 30-May 5, 2011; Fort Lauderdale, FL.
29. Food and Drug Administration. Center for Drug Evaluation and Research. Zirgan Clin Pharmacol Biopharm Rev Available at http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2009/022211-zirgan-toc.cfm. Accessed 3 June 2011.
30. Pouliquen P, Elena PP, Malecaze F. Assessment of the safety and local pharmacokinetics of a 0.15% gel of ganciclovir (Virgan) in healthy volunteers. Invest Ophthalmol Vis Sci 1996;37:S313. (Pubitemid 126822911)
31. Naito T, Nitta K, Kinouchi Y, Shiota H, Mimura Y. Effects of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) eye drops and cyclosporine eye drops in the treatment of herpetic stromal keratitis in rabbits. Curr Eye Res 1991;10 Suppl:201-203.
32. Gordon YJ, Capone A, Sheppard J, Gordon A, Romanowski E, Araullo-Cruz T. 2′-nor-cGMP, a new cyclic derivative of 2′NDG, inhibits HSV-1 replication in vitro and in the mouse keratitis model. Curr Eye Res 1987;6:247-253. (Pubitemid 17007681)
33. Colin J, Hoh HB, Easty DL et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Cornea 1997;16:393-399. (Pubitemid 27282176)
34. Ramirez JB, Baca O, Velasco R, Viggiano D, Erazo J. Topical treatment for epithelial herpetic keratitis: ganciclovir gel vs aciclovir ointment. Invest Ophthalmol Vis Sci 2002;43:E-abstract 3072.
35. Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2010;12:CD002898.
36. Foster CS. Ganciclovir gel - a new topical treatment for herpetic keratitis. US Ophthamol Rev Touch Briefings 2008;3:52-56.
37. Bausch & Lomb, Inc. Ganciclovir reports of postmarketing experience. June 14, 2010.
38. Laboratoires THEA. Virgan 1.5 mg/g eye gel: pharmacovigilance data. 63017 Clermont-Ferrand Cedex 2, France. February 8, 2008.
39. Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004;39 Suppl 5:S248-S257. (Pubitemid 39447300)
40. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003;16:114-128. (Pubitemid 36114710)
41. Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 2008;198:659-663.
42. Tabbara KF. Treatment of herpetic keratitis. Ophthalmology 2005;112:1640.
43. Tabbara KF, Jarade EF. Ganciclovir effects in adenoviral keratoconjunctivitis. Invest Ophthalmol Vis Sci 2001;42:S579. Abstract 3111-B253.
44. Vérin PH, Mortemousque B, Barach D. Ganciclovir 0.15% gel, a new treatment in epidemic keratoconjunctivitis (EKC). Ophthalmic Res 1997;29(suppl 1):12-27.
45. Sirion Therapeutics, Inc. New drug application for ganciclovir is accepted for review by the FDA for the treatment of ocular herpes [news release]. Medical News Today. January 27, 2009. http://www.medicalnewstoday.com/ releases/136720.php. Accessed 15 May 2012.
46. Bausch + Lomb acquires Zirgan® (ganciclovir ophthalmic gel 0.15%) from Sirion Therapeutics for the treatment of herpetic keratitis [news release]. Rochester, NY: Bausch + Lomb Incorporated; http://bauschlocal.com/zirgan/ zirganPressRelease.html. Accessed 15 May 2012.
47. US Department of Health and Human Services. NDA Approval Letter, Application Number 22-211. Silver Spring, MD: Center for Drug Evaluation and Research. 2009.